Merck & Co., Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Robert M. Davis J.D.
- Full Time Employees
- 73,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2000 Galloping Hill Road Rahway NJ United States of America 07033
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Company News
4 BofA Securities Strong Buy Growth 10 Stocks Also Pay Reliable Dividends
Why the Market Dipped But Merck (MRK) Gained Today
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
2 Dividend Stocks to Buy and Never Sell
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
2 Wonderful Dividends Practically Giving Themselves Away
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Here's Why Merck (MRK) Fell More Than Broader Market
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Merck (MRK) Rises Higher Than Market: Key Facts